Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Next Science's revenue for the
six
months ended in Jun. 2025 was $10.49 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2025 was $22.07 Mil.
Next Science's Revenue per Share for the
six
months ended in Jun. 2025 was $0.04.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2025 was $0.08.
Warning Sign:
Next Science Ltd revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Next Science was -12.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 20.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 37.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 7 years, Next Science's highest 3-Year average Revenue per Share Growth Rate was 74.10% per year. The lowest was 20.10% per year. And the median was 32.60% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Next Science Revenue Related Terms
Next Science Revenue Historical Data
* Premium members only.
The historical data trend for Next Science's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Next Science's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Next Science Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Next Science's Revenue distribution charts can be found below:
* The bar in red indicates where Next Science's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $22.07 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Next Science (NXSCF) has a Revenue of $22.07 Mil as of Jun. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Next Science and its competitors.
Is Next Science's Revenue too high?
Next Science's current Revenue is $22.07 Mil.
How does Next Science's Revenue compare to GCAN and PTPI?
Next Science's Revenue of $22.07 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Next Science and its competitors. Next Science's current Revenue is $22.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Next Science stock overvalued right now?
Next Science (NXSCF) has a current Revenue of $22.07 Mil. The stock's GF Value™ is $0.26, compared to a current price of $0.00 — trading 99.6% below its estimated fair value. The current Revenue is $22.07 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Next Science (NXSCF), the current Revenue is $22.07 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with efficacy in eradicating both biofilm-based and free-floating bacteria. Its products include Bactisure, XEPERIENCE and BLASTX. The company derives revenue from North America, New Zealand, and Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NXSCF has been successfully added to your 
